Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenza H5N1



Status:Archived
Conditions:Influenza
Therapuetic Areas:Immunology / Infectious Diseases
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:October 2009
End Date:October 2010

Use our guide to learn which trials are right for you!

Phase 1 Evaluation of the Safety and Immunogenicity of a Replication-Competent Adenovirus Serotype 4-vectored H5N1 Influenza Candidate Vaccine - Ad4-H5-Vtn


The purpose of this study is to compare the safety and immunogenicity over an 8-month period
of three different dosages of Ad4-H5-Vtn in volunteers (Vaccinees) who receive two doses of
the study vaccine or placebo. In addition, transmission of Ad4-H5-Vtn will be evaluated in
all Household Contacts residing with the vaccinated volunteers.


At least 96 healthy Vaccinees will be randomized into 3 ascending dosage cohorts each
consisting of at least 32 volunteers. In each dosage cohort Vaccinees will be randomly
assigned to receive 2 doses of either Ad4-H5-Vtn or placebo separated by approximately 56
days. Volunteers will be followed for 180 days post-second vaccination.


We found this trial at
5
sites
Albany, New York
?
mi
from
Albany, NY
Click here to add this to my saved trials
Celebration, Florida
?
mi
from
Celebration, FL
Click here to add this to my saved trials
Charleston, South Carolina
?
mi
from
Charleston, SC
Click here to add this to my saved trials
Louisville, Kentucky
?
mi
from
Louisville, KY
Click here to add this to my saved trials
St Louis, Missouri
?
mi
from
St Louis, MO
Click here to add this to my saved trials